Who is sponsoring NCT04992377?

NCT04992377 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT04992377?

Interventions in NCT04992377: R-EPOCH in Combination With Ibrutinib.

What condition does NCT04992377 study?

NCT04992377 studies Richter Transformation.

Is NCT04992377 still recruiting?

NCT04992377 is currently status unknown. Last updated 5 August 2021.

Last reviewed 2021-08-05 · How we verify

NCT04992377: BDHRT001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Status unknown Phase 2 Last updated 5 August 2021

What this trial tests

Phase 2 trial testing R-EPOCH in Combination With Ibrutinib in Richter Transformation in 30 participants. Status unknown.

Timeline

30 August 2021

Primary endpoint
30 August 2024

30 August 2025

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	30 August 2021
Primary completion	30 August 2024
Estimated completion	30 August 2025
Sites	11 locations across China

Drugs / interventions tested

R-EPOCH in Combination With Ibrutinib — full drug profile →

Conditions studied

Richter Transformation — all drugs for Richter Transformation →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 65, any sex, with Richter Transformation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigator-initiated Phase 2 study, which combines R-EDOCH with Ibrutinib to treat patients with Ritcher Transformation in consideration of DLBCL and CLL components both could being targeted at the same time. The investigator will observe the 2-year overall survival rate of this regimen for RT and explore the new regimen for RT in the novel drugs era, which aims to improve the efficacy and prolong survival.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Biology and Treatment of Richter Transformation.
Condoluci A, Rossi D. · · 2022 · cited 39× · PMID 35392219 · DOI 10.3389/fonc.2022.829983
Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era.
Briski R, Taylor J. · · 2023 · cited 13× · PMID 36980742 · DOI 10.3390/cancers15061857
Novel Approaches for the Treatment of Patients with Richter's Syndrome.
Iannello A, Deaglio S, Vaisitti T. · · 2022 · cited 5× · PMID 35294723 · DOI 10.1007/s11864-022-00973-1

Verify or expand the search:

Other recruiting trials for Richter Transformation

Currently open trials in the same condition.

NCT05107674 — A Study of NX-1607 in Adults With Advanced Malignancies · Phase 1 · recruiting
NCT04771572 — Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN- · Phase 1 · recruiting
NCT04792489 — DALY II USA/ MB-CART2019.1 for DLBCL · Phase 2 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04992377 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 5 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04992377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing